Specific activation of resting T cells against CA19-9+ tumor cells by an anti-CD3/CA19-9 bispecific antibody in combination with a costimulatory anti-CD28 antibody

Journal of Immunotherapy

Volumn 20, Issue 5, 1997, Pages 325-333

  Hombach, Andreas ^a   Tillmann, Thorsten ^a   Jensen, Markus ^a   Heuser, Claudia ^a   Sircar, Ranjan ^a   Diehl, Volker ^a   Kruis, Wolfgang ^b   Pohl, Christoph ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Evangelisches Krankenhaus Koln Kalk   (Germany)

Author keywords

Adoptive immunotherapy; Bispecific antibodies; Cytokine network; T cell immunology; Tumor targeting

Indexed keywords

BISPECIFIC ANTIBODY; CA 19-9 ANTIGEN; CD3 ANTIGEN; GAMMA INTERFERON; MONOCLONAL ANTIBODY; OKT 3;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY TEST; HUMAN; HUMAN CELL; HYBRIDOMA; LYMPHOCYTE PROLIFERATION; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0031434631     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199709000-00001     Document Type: Article

References (27)

1. Pohl C, Denfeld R, Renner C, et al. CD30-antigen specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin’s lymphoma. Int J Cancer 1993;54:820-7.
2. Renner C, Pfreundschuh M. Tumor therapy by immune recruitment with bispecific antibodies. Immunol Rev 1995;145:179-209.
3. Pupa S, Canevari S, Fontanelli R, et al. Activation of mononuclear cells to be used for hybrid monoclonal antibody induced lysis of human carcinoma cells. Int J Cancer 1988;42:455-9.
4. Hathcock KS, Laszlo G, Pucillo C, Linsley P, Hodes RJ. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J Exp Med 1994; 180:63.
5. Robey E, Allison JP. T cell activation: integration of signals from the antigen receptor and costimulatory molecules. Immunol Today 1995;16:306-10.
6. Björndahl ML, Sung SS, Hansen JA, Fu SM. Human T cell activation: differential response to anti-CD28 as compared to anti-CD3 monoclonal antibodies. Eur J Immunol 1989;19:817-87.
7. August A, Dupont B. CD28 of T lymphocytes associates with phosphatidylinositol 3-kinase. Int Immunol 1994;6:769-74.
8. Renner C, Jung W, Sahin U, et al. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science 1994;264:833-5.
9. Jung G, Ledbetter JA, Müller-Eberhard HJ. Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates. Proc Natl Acad Sei USA 1987; 84: 4611-5.
10. Bohlen H, Hopff T, Manzke O, et al. Lysis of malignant B-cells from patients with B-chronic lymphocytic leucemia by autologous T cells activated with CD3 X CD 19 bispecific antibodies in combination with bivalent CD28 antibodies. Blood 1993;82:1803-12.
11. Klug TL, LeDonne NC, Greber TF, Zurawski VR Jr. Purification and composition of a novel gastrointestinal tumor-associated glycoprotein expressing sialylated lacto-N-fucopentaose II (CA 19-9). Cancer Res 1989;48:1505-11.
12. Ohishio G, Ogawa K, Kudo H, et al. Immunohistochemical studies on the localization of cancer associated antigens DU-PAN-2 and CA19-9 in the carcinomas of the digestive tract. J Gastroenterol Hepatol 1990;5:25-31.
13. VanLier RA, Brouwer M, DeJong R, Groot M, Groot E, Arden LA. Functional properties of the human T cell differentiation antigen CD28. In: Knapp W et al., eds. Leukocyte typing IV. Oxford: Oxford University Press, 1989:353-5.
14. Miltenyi S, Müller W, Weichei W, Radbruch A. High gradient magnetic cell separation with MACS. Cytometry 1990;11:231-8.
15. Hombach A, Jung W, Pohl C, et al. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin’s cells by unstimulated natural killer cells in vitro and in vivo. Int J Cancer 1993; 55:830-6.
16. Muir D, Varon S, Manthorpe M. An enzyme-linked immunosorbent assay for bromodeoxyuridine incorporation using fixed microcultures. Anal Biochem 1990;185:377-82.
17. Wemme W, Pfeifer S, Heck R, Müller-Quernheim J. Measurement of lymphocyte proliferation: critical analysis of radioactive and photometric methods. Immunobiology 1992;185:78-89.
18. Blomberg K, Ulfstedt AC. Fluorescent europium chelates as target cell markers in the assessment of natural killer cell cytotoxicity. J Immunol Methods 1993;160:27-34.
19. Renner C, Jung W, Sahin U, van Lier R, Pfreundschuh M. The role of lymphocyte subsets and adhesion molecules in T cell-dependent cytotoxicity mediated by CD3 and CD28 bispecific monoclonal antibodies. Eur J Immunol 1995;25:2027-33.
20. De Palazzo IG, Gercel-Taylor C, Kitson J, Weiner LM. Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fc gamma receptor expressed by human large granular lymphocytes. Cancer Res 1990;50:7123-8.
21. Moretta A, Ciccione E, Pantaleo E, et al. Surface molecules involved in the activation and regulation of T cells or natural killer lymphocytes in humans. Immunol Rev 1988; 145-75.
22. Schwinzer R, Franklin RA, Domenico J, Renz H, Gelfand EW. Monoclonal antibodies directed to different epitopes in the CD3-TCR complex induce different states of competence in resting human T cells. J Immunol 1992;148:1322-8.
23. VanDijk J, Warnaaar SO, van Eendenburg JDH, et al. Induction of tumor-cell lysis by bispecific monoclonal antibodies recognizing renal cell carcinoma and CD3 antigen. Int J Cancer 1989; 43: 344-9.
24. Lamers CH, van de Griend RJ, Braakman E, et al. Optimization of culture conditions for activation and large-scale expansion of human T lymphocytes for bispecific antibody-directed cellular immunotherapy. Int J Cancer 1992;51:973-9.
25. June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today 1994;15:321-31.
26. Guadagni F, Schlom J, Johnston WW, et al. Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells. J Natl Cancer Inst 1989;81:502-12.
27. Daniel PT, Kroidl A, Bommert K, et al. Costimulation with agonistic anti-CD28 antibodies prevents T-cell apoptosis and is required for efficient immunotherapy with CD3X19 bispecific antibodies in B cell lymphoma. Ann Hematol 1996;73(suppl):175.